{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:30:59Z","timestamp":1790310659267,"version":"4.1.0"},"reference-count":31,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,5,31]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab. There is therefore an absence of prospective clinical trial evidence regarding the efficacy of checkpoint inhibitors (CPIs) in this population. Acral melanoma has lower tumor mutation burden (TMB) than other cutaneous sites, and primary site is associated with differences in TMB. However the impact of this on the effectiveness of immune CPIs is unknown. We examined the efficacy of CPIs in acral melanoma, including by primary site.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with unresectable stage III\/IV acral melanoma treated with CPI (anti-PD-1 and\/or ipilimumab) were studied. Multivariable logistic and Cox regression analyses were conducted. Primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 325 patients were included: 234 (72%) plantar, 69 (21%) subungual and 22 (7%) palmar primary sites. First CPI included: 184 (57%) anti-PD-1, 59 (18%) anti-PD-1\/ipilimumab combination and 82 (25%) ipilimumab. ORR was significantly higher with initial anti-PD-1\/ipilimumab compared with anti-PD-1 (43% vs 26%, HR 2.14, p=0.0004) and significantly lower with ipilimumab (15% vs 26%, HR 0.49, p=0.0016). Landmark PFS at 1 year was highest for anti-PD-1\/ipilimumab at 34% (95% CI 24% to 49%), compared with 26% (95% CI 20% to 33%) with anti-PD-1 and 10% (95% CI 5% to 19%) with ipilimumab. Despite a trend for increased PFS, anti-PD-1\/ipilimumab combination did not significantly improve PFS (HR 0.85, p=0.35) or OS over anti-PD-1 (HR 1.30, p=0.16), potentially due to subsequent therapies and high rates of acquired resistance. No outcome differences were found between primary sites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>While the ORR to anti-PD-1\/ipilimumab was significantly higher than anti-PD-1 and PFS numerically higher, in this retrospective cohort this benefit did not translate to improved OS. Future trials should specifically include patients with acral melanoma, to help determine the optimal management of this important melanoma subtype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-004668","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T12:11:39Z","timestamp":1657109499000},"page":"e004668","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-8467","authenticated-orcid":false,"given":"Prachi","family":"Bhave","sequence":"first","affiliation":[{"name":"Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnia","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-5544","authenticated-orcid":false,"given":"Serigne N","family":"Lo","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4412","authenticated-orcid":false,"given":"Alexander","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Medicine, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zaremba","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M","family":"Versluis","sequence":"additional","affiliation":[{"name":"Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Z\u00fcrich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-4961","authenticated-orcid":false,"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcoma, Peking University Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[{"name":"Research and Medical Oncology, Centre Eug\u00e8ne Marquis, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Dermatology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trojanello","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione \"G.Pascale\", Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Wicky","sequence":"additional","affiliation":[{"name":"Oncology, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Heywood","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Tran","sequence":"additional","affiliation":[{"name":"Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Batty","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"},{"name":"Dermatology, University Hospital Z\u00fcrich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stansfeld","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Allayous","sequence":"additional","affiliation":[{"name":"Dermatology, Saint-Louis hospital, INSERM U976, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-5380","authenticated-orcid":false,"given":"Julia K","family":"Schwarze","sequence":"additional","affiliation":[{"name":"Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-8015","authenticated-orcid":false,"given":"Meghan J","family":"Mooradian","sequence":"additional","affiliation":[{"name":"Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-9553","authenticated-orcid":false,"given":"Oliver","family":"Klein","sequence":"additional","affiliation":[{"name":"Medical Oncology, Olivia Newton John Cancer Centre, Austin Health, Melbourne, Victoria, Australia"},{"name":"Medical Oncology, Warrnambool Hospital, Warrnambool, Victoria, Australia"},{"name":"Medical Oncology, Peninsula Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderjit","family":"Mehmi","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts-Thomson","sequence":"additional","affiliation":[{"name":"Medical Oncology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Maurichi","sequence":"additional","affiliation":[{"name":"Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Yeoh","sequence":"additional","affiliation":[{"name":"Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[{"name":"Medical Oncology, Fiona Stanley Hospital & Edith Cowan Univserity, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U","family":"Blank","sequence":"additional","affiliation":[{"name":"Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Z\u00fcrich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C","family":"K\u00e4hler","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Roy","sequence":"additional","affiliation":[{"name":"Dermatology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione \"G.Pascale\", Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[{"name":"Oncology, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Lorigan","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebbe","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, AP-HP Department of Dermatology, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-5903","authenticated-orcid":false,"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Santinami","sequence":"additional","affiliation":[{"name":"Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A","family":"McArthur","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Haydon","sequence":"additional","affiliation":[{"name":"Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S","family":"Carlino","sequence":"additional","affiliation":[{"name":"Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia"},{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2025100305030501000_10.7.e004668.1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.602705","article-title":"Immune checkpoint inhibitors in advanced acral melanoma: a systematic review","volume":"10","author":"Zheng","year":"2020","journal-title":"Front Oncol"},{"key":"2025100305030501000_10.7.e004668.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.031"},{"key":"2025100305030501000_10.7.e004668.3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdin.2020.07.004","article-title":"The tumor genetics of acral melanoma: what should a dermatologist know?","volume":"1","author":"Tod","year":"2020","journal-title":"JAAD Int"},{"key":"2025100305030501000_10.7.e004668.4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz005"},{"key":"2025100305030501000_10.7.e004668.5","doi-asserted-by":"publisher","DOI":"10.1038\/nature22071"},{"key":"2025100305030501000_10.7.e004668.6","doi-asserted-by":"publisher","DOI":"10.1101\/gr.213348.116"},{"key":"2025100305030501000_10.7.e004668.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30259"},{"key":"2025100305030501000_10.7.e004668.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000341","article-title":"Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma","volume":"8","author":"Klemen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100305030501000_10.7.e004668.9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/CMR.0000000000000465","article-title":"Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis","volume":"28","author":"H\u00e4fliger","year":"2018","journal-title":"Melanoma Res"},{"key":"2025100305030501000_10.7.e004668.10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/CMR.0000000000000764","article-title":"Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis","volume":"31","author":"Cho","year":"2021","journal-title":"Melanoma Res"},{"key":"2025100305030501000_10.7.e004668.11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2019.07.008","article-title":"Clinical and genetic analysis of melanomas arising in acral sites","volume":"119","author":"Zaremba","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100305030501000_10.7.e004668.12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100305030501000_10.7.e004668.13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/bjd.17434","article-title":"Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients","volume":"180","author":"Maeda","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025100305030501000_10.7.e004668.14","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"2025100305030501000_10.7.e004668.15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (PTS) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100305030501000_10.7.e004668.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100305030501000_10.7.e004668.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7836"},{"key":"2025100305030501000_10.7.e004668.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"2025100305030501000_10.7.e004668.19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100305030501000_10.7.e004668.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13889-6"},{"key":"2025100305030501000_10.7.e004668.21","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2016.143"},{"key":"2025100305030501000_10.7.e004668.22","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12279"},{"key":"2025100305030501000_10.7.e004668.23","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s12094-017-1685-3","article-title":"Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America","volume":"19","author":"Castaneda","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"2025100305030501000_10.7.e004668.24","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1245\/s10434-020-08418-5","article-title":"The clinicopathological and survival profiles comparison across primary sites in acral melanoma","volume":"27","author":"Wei","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2025100305030501000_10.7.e004668.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1630"},{"key":"2025100305030501000_10.7.e004668.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9275"},{"key":"2025100305030501000_10.7.e004668.27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627548"},{"key":"2025100305030501000_10.7.e004668.28","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"The Lancet"},{"key":"2025100305030501000_10.7.e004668.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.10.017"},{"key":"2025100305030501000_10.7.e004668.30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41586-022-04584-6","article-title":"Anatomic position determines oncogenic specificity in melanoma","volume":"604","author":"Weiss","year":"2022","journal-title":"Nature"},{"key":"2025100305030501000_10.7.e004668.31","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0522"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:03:19Z","timestamp":1759492999000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,6]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/jitc-2022-004668"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004668","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}